New York Times,
July 22, 2008
Sirtris, a drug company, has two drugs in clinical trials that it hopes will avert degenerative diseases of aging.
One being tested in diabetic patients is a special formulation of resveratrol that delivers a bloodstream dose five times as high as the chemical alone, to reduce glucose levels.
The other drug is a small synthetic chemical that is a thousand times as potent as resveratrol in activating sirtuin and can be given at a much smaller dose.
The hope is that activating sirtuins in people would, like a calorically restricted diet in mice, avert degenerative diseases of aging like diabetes, heart disease, cancer and Alzheimer's.
Read Original Article>>
|
